Candidate-gene approach in fibromyalgia syndrome: Association analysis of the genes encoding substance P receptor, dopamine transporter and αl-antitrypsin

Clinical and Experimental Rheumatology

Volumn 27, Issue 5 SUPPL. 56, 2009, Pages

  Ablin, J N ^a   Bar Shira, A ^a   Yaron, M ^a   Orr Urtreger, A ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Alpha 1 antitrypsin; Dopamin transporter; Fibromyalgia; Genetics; Substance P receptor

Indexed keywords

ALPHA 1 ANTITRYPSIN; DOPAMINE TRANSPORTER; NEUROKININ 1 RECEPTOR; SLC6A3 PROTEIN, HUMAN;

ADULT; ALLELE; ARTICLE; CHI SQUARE DISTRIBUTION; FEMALE; FIBROMYALGIA; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; ISRAEL; JEW; MALE; MIDDLE AGED; MUTATION; RISK; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ALPHA 1-ANTITRYPSIN; CHI-SQUARE DISTRIBUTION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FIBROMYALGIA; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; ISRAEL; JEWS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, NEUROKININ-1;

EID: 77950355732     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. MAS AJ, CARMONA L, VALVERDE M, RIBAS B; EPISER STUDY GROUP: Prevalence and impact of fibromyalgia on function and quality of life in individuals from the general population: results from a nationwide study in Spain. Clin Exp Rheumatol 2008; 26: 519-26.
2. CROFFORD LJ, CLAUW D: Fibromyalgia: where are we a decade after the American College of Rheumatology classification criteria were developed? Arthritis Rheum 2002; 46: 1136-8.
3. ORELLANA C, CASADO E, MASIP M et al.: Sexual dysfunction in fibromyalgia patients. Clin Exp Rheumatol 2008; 26: 663-6.
4. BAZZICHI L, ROSSI A, MASSIMETTI G et al.: Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol 2007; 25: 225-30.
5. HSU MC, CLAUW D: A different type of procedure for a different type of pain. Arthritis Rheum 2006; 54: 3725-7.
6. ARNOLD LM, LU Y, CROFFORD LJ et al.: A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-84.
7. CROFFORD LJ. ROWBOTHAM M, MEASE PJ et al.: Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-73.
8. LITTLEJOHN G: Balanced treatments for fibromyalgia. Arthritis Rheum 2004; 50: 2725-2729
9. MEASE P: Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol Suppl 2005; 75: 6-21.
10. PELLEGRINO MJ, WAYLONIS G, SOMMER A: Familial occurrence of primary fibromyalgia. Arch Phys Med Rehahil 1989; 70: 61-63.
11. BUSKILA D, NEUMANN L, HAZANOV I et al: Familial aggregation in the fibromyalgia syndrome. Semin Arthritis Rheum 1997; 26: 605-11.
12. ARNOLD LM. HUDSON J. HESS EV et al.: Family study of fibromyalgia. Arthritis-Rheum 2004; 50: 944-52.
13. YUNUS MB, KHAN M, RAWLINGS KK et al.: Genetic linkage analysis of multicase families with fibromyalgia syndrome. J Rheumatol 1999; 26: 408-12.
14. AARON LA. HERRELL R. ASHTON S et al: Comorbid clinical conditions in chronic fatigue: a cotwin control study. J Gen Intern Med 2001; 16:24-31.
15. OFFENBAECHER M, BONDY B, DE JONGE S et al.: Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis Rheum 1999;42:2482-8.
16. COHEN H, BUSKILA D, NEUMANN L et al.: Confirmation of an association between fibromyalgia and serotonin transporter promoter region (5- HTTLPR) polymorphism, and relationship to anxiety-related personality traits. Arthritis Rheum 2002; 46: 845-7.
17. BUSKILA D. COHEN H, NEUMANN L et al.: An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004; 9:730-1.
18. GURSOY S, ERDAL E, HERKEN H et al.: Significance of catechol-O- methyltrans-ferase gene polymorphism in fibromyalgia syndrome. Rheumatol Int 2003; 23: 104-7.
19. CLAUW DJ, BELFER I, MAX M et al.: Increased frequency of the minor allele for beta-3 adrenergic receptors in individuals with fibromyalgia and related syndromes. In: ACRIARHP Annual Scientific Meeting 2007. Boston, MA; 2007.
20. GURSOY S, ERDAL E, HERKEN H et al.: Association of T102C polymorphism of the 5-HT2A receptor gene with psychiatric status in fibromyalgia syndrome. Rheumatol Int 2001;21:58-61.
21. ORR-URTREGER A, BAR-SHIR A A, BERCOV-ICH D et al: RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15: 474-9.
22. WOLFE F, SH, YUNUS MB et al.: The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 160-72.
23. VAEROY H, HELLE R, FøRRE ø et al: Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in-patients with fibromyalgia: new features for diagnosis. Pain 1988; 32: 21-6.
24. RUSSELL LI, ORR M, LITTMAN B et al.: Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum 1994; 37: 1593-601.
25. LIU Z, WELIN M, BRAGEE B et al: Elevated substance P level in cerebrospinal fluid from patients with fibromyalgia is contrasted by a decrease in Met-enkephalin-Arg-Phe. Analgesia 1995; 1:4-6.
26. JASMIN L, TIEN D, WEINSHENKER D et al: The NK1 receptor mediates both the hyperalgesia and the resistance to morphine in mice lacking noradrenaline. Proc Natl Acad Sci U S A 2002; 99: 1029-34.
27. DE FELIPE C, HERRERO J, O'BRIEN JA et al: Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998: 392: 394-7.
28. QUARTARA L, MAGGI C: The tachykinin NK1 receptor. Part II: Distribution and patho-physiological roles. Neuropeptides 1998; 32: 1-49.
29. MCLEAN S: Do substance P and the NK.1 receptor have a role in depression and anxiety? Curr Pharm Des 2005; 11: 1529-47.
30. LECCI A, VALENTI C, MAGGI CA: Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs 2002; 3: 589-601.
31. DUFFY RA: Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs 2004; 9: 9-21.
32. RUSSELL LI: The promise of substance P inhibitors in fibromyalgia. Rheum Dis Clin North Am 2002; 28: 329-42.
33. WOOD PB, PATTERSON JN, SUNDERLAND JJ et al: Reduced presynaptic dopamine activity in fibromyalgia syndrome demonstrated with positron emission tomography: a pilot study. J Pain 2007; 8: 51-8.
34. HOLMAN AJ, MYERS R: A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005; 52: 2495-505.
35. BUSKILA D, COHEN H, NEUMANN L et al: An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004; 9:730-1.
36. MALT EA, OLAFSSON S, AAKVAAG A et al: Altered dopamine D2 receptor function in fibromyalgia patients: a neuroendocrine study with buspirone in women with fibromyalgia compared to female population based controls. J Affect Disord 2003; 75: 77-82.
37. CILIAX BJ, HEILMAN C, DEMCHYSHYN LL et al: The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 1995; 15: 1714-23.
38. MEHLER-WEX C, RIEDERER P, GERLACH M: Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res 2006; 10: 167-79.
39. GIROS B, EL MESTIKAWY S, GODINOT N et al: Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Mol Pharmacol 1992;42:383-90.
40. KAWARAI T, KAWAKAMI H, YAMAMURA Y et al: Structure and organization of the gene encoding human dopamine transporter. Gene 1997; 195: 11-8.
41. GIROS B, JABER M, JONES SR et al: Hyper-locomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-12.
42. SANO A, KONDOH K, KAKIMOTO Y et al: A 40-nucleotide repeat polymorphism in the human dopamine transporter gene. Hum Genet 1993; 91: 405-6.
43. CONNE B, STUTZ A, VASSALLI JD: The 3' untranslated region of messenger RNA: A molecular 'hotspot' for pathology? Nat Med 2000;6:637-41.
44. KANG AM, PALMATIER M, KIDD KK: Global variation of a 40-bp VNTR in the 3'-untrans-lated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 1999; 46: 151-60.
45. GILBERT DL, WANG Z, SALLEE FR et al: Dopamine transporter genotype influences the physiological response to medication in ADHD. Brain 2006; 129: 2038-46.
46. AMIR M, KAPLAN Z, NEUMANN L, SHARA-BANI R, SHANI N, BUSKILA D: Posttraumatic stress disorder, tenderness and fibromyalgia. J Psychosom Res 1997; 42: 607-13.
47. SHERMAN JJ, TURK D, OKIFUJI A: Prevalence and impact of posttraumatic stress disorderlike symptoms on patients with fibromyalgia syndrome. Clin J Pain 2000; 16: 127-34.
48. COHEN H, NEUMANN L, HAIMAN Y et al: Prevalence of post-traumatic stress disorder in fibromyalgia patients: overlapping syndromes or post-traumatic fibromyalgia syndrome? Semin Arthritis Rheum 2002; 32: 38-50.
49. SEGMAN RH, COOPER-KAZAZ R, MACCIAR-DI F et al.: Association between the dopamine transporter gene and posttraumatic stress disorder. Mol Psychiatry 2002; 7: 903-7.
50. LUISETTI M, SEERSHOLM N: Alphal-antit-rypsin deficiency. 1: epidemiology of alpha 1-antitrypsin deficiency. Thorax 2004; 59: 164-9.
51. DEMEO DL, SILVERMAN E: Alphal-anti-trypsin deficiency. 2: genetic aspects of al-pha(l)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59: 259-64.
52. LOMAS DA, PARFREY H: Alpha 1-antitrypsin deficiency. 4: Molecular pathophysiology. Thorax 2004; 59: 529-35.
53. BLANCO 1, CANTO H, DE SERRES FJ et al: Alpha 1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha 1-antitrypsin deficiency. J Rheumatol 2004; 31: 2082-5.
54. BLANCO LE, DE SERRES F, FERNANDEZ-BUSTILLO E et al: Alpha 1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 2005; 64: 759-69.
55. SLATKIN M: A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases. Am J Hum Genet 2004; 75: 282-93.
56. STRUEWING JP, HARTGE P, WACHOLDER S et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 15: 1401-8.
57. FOULKES WD, THIFFAULT I, GRUBER SB et al: The founder mutation MSH2*1906G-->C is an important cause of hereditary non-polyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 2002; 71: 1395-412.
58. FALLIN MD, LASSETER V, WOLYNIEC PS et al: Genomewide linkage scan for bipolardisorder susceptibility loci among Ashkenazi Jewish families. Am J Hum Genet 2004; 75: 204-19.
59. RENNERT H, BERCOVICH D, HUBERT A et al: A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet 2002; 71: 981-4.
60. PENNISIE: Breakthrough of the year. Human genetic variation. Science 2007; 318: 1842-3.